💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Vijaya Diagnostic Centre Limited is an India-based company, which is engaged in the business of providing a range of diagnostic services, spanning pathological investigations, basic and high-end radiology, nuclear medicine, and related healthcare services. It operates through…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, fast-growing business, priced for perfection.
Vijaya Diagnostic Center is scored on the pharma / healthcare framework. It keeps a fat 20.7% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.56× reported profit. Free cash flow is worth about 0.6% of its market value.
Over the last 3 years revenue compounded at 21%/yr and profit at 27%/yr. Book value itself has compounded 21%/yr — the hallmark of a genuine compounder. Return on equity is an elite 19.3%. In the latest quarter profit grew 11% versus the prior quarter.
At 87× earnings, the stock sits at the 89th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~27%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 74.25 | 75.62 | better |
| P/B | 14.31 | 3.49 | worse |
| EV/EBITDA | 36.9 | 19.95 | worse |
| ROE | 19.26 | — | — |
| ROCE | 19.99 | 10.81 | better |
| ROA | 11.75 | 3.84 | better |
| Quick Ratio | 2.56 | — | — |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Apollo Hospitals | 52.0 | 11.4 | 21.1% |
| Max Healthcare | 65.9 | 8.0 | 12.2% |
| Manipal Health Enterprises | 93.9 | 5.2 | 10.6% |
Revenue has grown every year across all 4 financial years shown. 21% CAGR over 3 years — high-growth territory.
Net profit has risen every year — the hallmark of a compounder. Profit is growing faster than revenue (27% vs 21%) — margin expansion is at work.
Operating margin has expanded from 24% to 28% — the business is keeping more of each rupee earned.
ROE at 18% — a respectable return on shareholder capital. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. 27% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Cash conversion at 1.6× PAT — earnings are well-backed by cash; strong accrual quality. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 8% sequentially — momentum is building. Run-rate stepping up — recent quarters average 10% above earlier ones.
Profit jumped 11% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoter holding at 52.5% — majority control intact. FIIs trimmed 4.4pp — foreign money is rotating out. MF holding up 3.5pp — domestic institutional discovery underway.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.